title: Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic prostate cancer a prognostic factor for outcome?
abstract: We evaluated the usefulness of overexpression of neuroendrocrine (NE) cell differentiation determined by immunohistochemical staining for chromogranin A (Cg A) in diagnostic needle biopsy specimens of bone metastatic prostate cancers. A total of 50 patients diagnosed as having bone metastatic prostate cancer were studied. The period of observation was between 6.9 and 79.4 months (median 48.7 months). Cg A was detected by immunostaining using the labeled streptavidin biotin method. Cg A-positivity was defined as the presence of immunostained cells in 10% or more of the tumor. All statistical analyses were carried out using the Statistical Package for Social Sciences Software, version 10.0 for Windows. Eleven patients (22%) were classified into the Cg A-positive group. There were no significant differences in clinical data between the Cg A-positive and Cg A-negative groups. The 5-year cause-specific survival rate was 34.1% for the Cg A-positive group and 55.2% for the Cg A-negative group (p=0.3763). The 3-year non-recurrence rate was 9.1% for the Cg A-positive group and 35.9% for the Cg A-negative group, and this difference was significant (p=0.0253). The 3-year cause-specific survival rates after recurrence were 38.4% and 42.3% respectively (p=0.8125). We consider that NE cell differentiation of the primary tumor in cases of bone metastatic prostate cancer is not a prognostic factor for outcome.
authors.affiliation: Department of Urology, Aichi Medical University School of Medicine, Aichi 480-1195, Japan. 101959@gk.amu.aichi-med-u.ac.jp
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Yamada
authors.forename: Kogenta
authors.initials: K
authors.lastname: Nakamura
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Aoki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Taki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Matsubara
authors.forename: Shotoku
authors.initials: S
authors.lastname: Sai
authors.forename: Katsuya
authors.initials: K
authors.lastname: Naruse
authors.forename: Motoi
authors.initials: M
authors.lastname: Tobiume
authors.forename: Remi
authors.initials: R
authors.lastname: Katsuda
authors.forename: Kenji
authors.initials: K
authors.lastname: Zennami
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Honda
authors.forename: Atsuko
authors.initials: A
authors.lastname: Nakagawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ikeda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001859:Bone Neoplasms / Q000378:metabolism / Q000556:secondary*; D002454:Cell Differentiation; D053379:Chromogranin A; D002864:Chromogranins / Q000378:metabolism*; D018572:Disease-Free Survival; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists; D014408:Biomarkers, Tumor; C506150:CHGA protein, human; D053379:Chromogranin A; D002864:Chromogranins